Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $4,917 | $5,255 | $2,953 | $4,350 |
| - Cash | $321 | $2,059 | $4,862 | $149 |
| + Debt | $69 | $90 | $111 | $131 |
| Enterprise Value | $4,664 | $3,286 | -$1,797 | $4,332 |
| Revenue | $0 | $0 | $1,000 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$22 | -$22 | -$886 | -$22 |
| % Margin | – | – | -88.6% | – |
| EBITDA | -$3,754 | -$4,207 | -$2,827 | -$3,152 |
| % Margin | – | – | -282.7% | – |
| Net Income | -$3,776 | -$3,491 | -$3,161 | -$3,129 |
| % Margin | – | – | -316.1% | – |
| EPS Diluted | -0.95 | -0.89 | -1.56 | -4.81 |
| % Growth | -6.7% | 42.9% | 67.6% | – |
| Operating Cash Flow | -$1,759 | -$2,471 | -$2,910 | -$3,170 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,759 | -$2,471 | -$2,910 | -$3,170 |